Not exact matches
«Dendritic cells are essential for prompting the immune response against malignant cells and for driving the clinical success of cancer immunotherapy, but their function is often defective in cancer patients,» said Dmitry I. Gabrilovich, M.D., Ph.D., Christopher M. Davis Professor and
program leader of the Immunology, Microenvironment & Metastasis Program at
program leader of the
Immunology, Microenvironment & Metastasis
Program at
Program at Wistar.
PHILADELPHIA --(July 11, 2017)-- Researchers at The Wistar Institute, an international
leader in biomedical research in the fields of cancer,
immunology and infectious diseases, with collaborators at Indiana University Melvin and Bren Simon Cancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (
programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).
She is a member of the Department of Pathology at Brigham and Women's Hospital, an Associate Member at the Broad Institute of MIT and Harvard, and
Leader of the Cancer
Immunology Program at the Dana - Farber / Harvard Cancer Center.
Ira Brind Professor Professor and Co-
Program Leader,
Immunology, Microenvironment and Metastasis
Program Member, The Wistar Institute Melanoma Research Center
In 2016, Dmitry I. Gabrilovich, M.D., Ph.D.,
program leader of Wistar's Translational Tumor
Immunology program, and his research team identified a marker for myeloid - derived suppressor cells (MDSCs), a population of immune cells implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy.
The
program will focus on «Translating Science into Survival» and feature talks from more than 60
leaders in the field covering all areas of inquiry in cancer
immunology and immunotherapy.